Bavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"
Bavarian Nordic’s recent deal in China has some pundits guessing that more partnerships are on the way. Even so, the company’s CFO Henrik Juuel says if the bidders aren’t the right size, it might be in Bavarian’s best interest to commercialize its RSV vaccine itself.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
As the ink dries on the deal Bavarian Nordic just signed with a Shanghai-based partner, a question emerges: Having found a partner in China, what will the Danish pharmaceutical firm do with its RSV vaccine candidate in the US and Europe?
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic could be first on the RSV market in China
For subscribers
